EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Subacute Therapeutic Dosing of Artemether-Lumefantrine and Artesunate-Amodiaquine Combination Preserves Plasma Cholesterol, Renal Antioxidant Status, and Organ Weights in Rats

Chiagoziem A Otuechere, Gloria Edewor, Oluwafemi Ezekiel Kale, Martins Ekor

Malaria Research and Treatment · 2012

DOI: 10.1155/2012/257986 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Malaria Research and Treatment, 2012. Verfasst von Chiagoziem A Otuechere und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Sciences, Redeemer's University, PMB 2011, Mowe, Ogun, Nigeria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent instances of breakdowns of malaria control programs and the constant emergence of drug-resistant parasites to monotherapies have shored up the use of artemisinin-based combination therapy (ACT) as the malaria therapy of choice. We evaluated a subacute therapeutic dosing of artemether-lumefantrine and artesunate-amodiaquine on plasma cholesterol, renal antioxidants, and organ weights in rats. Sixteen albino rats were grouped into three. Group A ( n = 5 ) served as the control. Groups B ( n = 6 ) and C ( n = 5 ) were administered, twice daily, oral therapeutic doses of artemether-lumefantrine (1.14/6.86 mg/kg/d) and artesunate-amodiaquine (2.86/8.58 mg/kg/d), respectively, for seven days. From our results, ACTs did not significantly ( P > 0.05 ) alter catalase, superoxide dismutase, glutathione S-transferase, myeloperoxidase, and total glutathione levels when compared with the control. Plasma total cholesterol levels also decreased insignificantly ( P > 0.05 ). Organ-system weights were not significantly ( P > 0.05 ) different from control rats. Artesunate-amodiaquine, but not artemether-lumefantrine, significantly increased ( P < 0.05 ) lactate dehydrogenase activity and also afforded a 27.2% decrease in heart weight when compared with control. Also, both ACTs increased ( P < 0.05 ) lipid peroxidation. Overall, artesunate-amodiaquine and artemether-lumefantrine may preserve renal antioxidants and organ weights in vivo. However, caution is required above therapeutic indications or in chronic doses as this may predispose to renal oxidative stress.

Autor:innen und Institutionen

  • Department of Chemical Sciences, Redeemer's University, PMB 2011, Mowe, Ogun, Nigeria.

Zitieren

APA

Otuechere, C. A., Edewor, G., Kale, O. E., & Ekor, M. (2012). Subacute Therapeutic Dosing of Artemether-Lumefantrine and Artesunate-Amodiaquine Combination Preserves Plasma Cholesterol, Renal Antioxidant Status, and Organ Weights in Rats. Malaria Research and Treatment. https://doi.org/10.1155/2012/257986

Vancouver

Otuechere CA, Edewor G, Kale OE, Ekor M. Subacute Therapeutic Dosing of Artemether-Lumefantrine and Artesunate-Amodiaquine Combination Preserves Plasma Cholesterol, Renal Antioxidant Status, and Organ Weights in Rats. Malaria Research and Treatment. 2012. doi:10.1155/2012/257986

BibTeX
@article{Otuechere2012,
  author = {Otuechere, Chiagoziem A and Edewor, Gloria and Kale, Oluwafemi Ezekiel and Ekor, Martins},
  title = {Subacute Therapeutic Dosing of Artemether-Lumefantrine and Artesunate-Amodiaquine Combination Preserves Plasma Cholesterol, Renal Antioxidant Status, and Organ Weights in Rats},
  journal = {Malaria Research and Treatment},
  year = {2012},
  doi = {10.1155/2012/257986}
}
Kostenlos starten →